Media headlines about NewLink Genetics (NASDAQ:NLNK) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NewLink Genetics earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.8199871842746 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s rankings:
- NewLink Genetics (NLNK) Announces 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors (streetinsider.com)
- NewLink Genetics Corp Forecasted to Post FY2022 Earnings of ($1.05) Per Share (NLNK) (americanbankingnews.com)
- Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation (finance.yahoo.com)
- NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors (finance.yahoo.com)
- Investors Buy Large Volume of NewLink Genetics Call Options (NLNK) (americanbankingnews.com)
A number of research firms have commented on NLNK. Cantor Fitzgerald restated a “buy” rating and set a $26.00 price target on shares of NewLink Genetics in a research report on Monday, September 25th. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Wednesday, January 3rd. BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. ValuEngine downgraded shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. Finally, Bank of America began coverage on shares of NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. NewLink Genetics currently has a consensus rating of “Buy” and a consensus price target of $23.29.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
What are top analysts saying about NewLink Genetics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NewLink Genetics and related companies.